Shanghai Pharmaceuticals (601607.SH): Tofacitinib Citrate Sustained-Release Tablets Approved for Production

Stock News11-06

Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. ("Shangyao Zhongxi"), recently received the Drug Registration Certificate (Certificate No.: 2025S03257) issued by the National Medical Products Administration (NMPA) for Tofacitinib Citrate Sustained-Release Tablets, approving its production.

The medication is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Originally developed by Pfizer, it was first launched in the U.S. in 2016. In January 2024, Shangyao Zhongxi submitted a registration application for the drug to the NMPA, which was subsequently accepted.

As of the announcement date, the company has invested approximately RMB 19.42 million in R&D for this product.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192970202?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 17:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192970202","market":"sh","top_or_hot":-1,"title":"Shanghai Pharmaceuticals (601607.SH): Tofacitinib Citrate Sustained-Release Tablets Approved for Production","media":"Stock News","content":"<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received the Drug Registration Certificate (Certificate No.: 2025S03257) issued by the National Medical Products Administration (NMPA) for Tofacitinib Citrate Sustained-Release Tablets, approving its production.</p>\n<p>The medication is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Originally developed by Pfizer, it was first launched in the U.S. in 2016. In January 2024, Shangyao Zhongxi submitted a registration application for the drug to the NMPA, which was subsequently accepted.</p>\n<p>As of the announcement date, the company has invested approximately RMB 19.42 million in R&D for this product.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals (601607.SH): Tofacitinib Citrate Sustained-Release Tablets Approved for Production</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals (601607.SH): Tofacitinib Citrate Sustained-Release Tablets Approved for Production\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-06 17:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received the Drug Registration Certificate (Certificate No.: 2025S03257) issued by the National Medical Products Administration (NMPA) for Tofacitinib Citrate Sustained-Release Tablets, approving its production.</p>\n<p>The medication is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Originally developed by Pfizer, it was first launched in the U.S. in 2016. In January 2024, Shangyao Zhongxi submitted a registration application for the drug to the NMPA, which was subsequently accepted.</p>\n<p>As of the announcement date, the company has invested approximately RMB 19.42 million in R&D for this product.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0184","symbol_name":"上海国资改革","start_time":0,"source_url":"","article_id":"1192970202","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192970202","pubTimestamp":1762420698,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received the Drug Registration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0184":"上海国资改革","BK0028":"国家队","BK0099":"上海本地重组","BK0097":"医药电商","02607":"上海医药","BK0020":"浦东新区","BK1197":"保健护理产品经销商","BK0209":"零售","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念","BK0196":"行业龙头","BK0175":"白马股","BK0187":"一线龙头"},"translate_title":"上海医药（601607.SH）：枸橼酸托法替尼缓释片获批生产","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received the Drug Registration Certificate (Certificate No.: 2025S03257) issued by the National Medical Products Administration (NMPA) for Tofacitinib Citrate Sustained-Release Tablets, approving its production.\nThe medication is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Originally developed by Pfizer, it was first launched in the U.S. in 2016. In January 2024, Shangyao Zhongxi submitted a registration application for the drug to the NMPA, which was subsequently accepted.\nAs of the announcement date, the company has invested approximately RMB 19.42 million in R&D for this product.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192970202","isCrawlerRequest":true}